In addition, these findings indicate that SLC38A6 can become a pharmacologically manageable molecular target for developing new treatment strategies for bacterial pneumonia and sepsis-associated pulmonary inflammation. This evidence concerns the gene SLC38A6 and bacterial pneumonia.